This undated photo shows two employees working in a drug research and development laboratory in Dongguan, Guangdong province. (ZHAN YOUBING / FOR CHINA DAILY)
BEIJING – The National Medical Products Administration has given emergency approval to the registration application of two COVID-19 medicines, BRII-196 and BRII-198.
The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA
This is China's first approved COVID-19 virus-neutralizing antibody combination therapy with independent intellectual property rights.
The two medicines are used in combination to treat adult and adolescent patients with mild and moderate symptoms and with severe risk factors for progression, according to the NMPA. Specifically, the medicines are conditionally approved for adolescents ranging from 12 to 17 years of age with a body weight greater than 40 kg.
READ MORE: 2 Chinese anti-COVID-19 drug candidates in clinical trials
Tsinghua University, the Third People's Hospital of Shenzhen and Brii Biosciences have jointly developed the cocktail therapy of monoclonal antibodies BRII-196 and BRII-198, which are derived from antibodies isolated from people who have recovered from COVID-19.